Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ardelyx, Inc.
  6. News
  7. Summary
    ARDX   US0396971071

ARDELYX, INC.

(ARDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday

07/20/2021 | 09:13am EDT


ę MT Newswires 2021
All news about ARDELYX, INC.
09/24ARDX DEADLINE ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Ardelyx, Inc. Shareholder..
BU
09/22ARDX DEADLINE ALERT : ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Encourages Ardelyx, Inc...
PR
09/22SCOTT+SCOTT ATTORNEYS AT LAW LLP REM : Ardx)
BU
09/20ARDELYX, INC.(NASDAQGM : ARDX) dropped from S&P Biotechnology Select Industry Index
CI
09/17KESSLER TOPAZ MELTZER & CHECK, LLP : Reminds Investors of Deadline for Securities Fraud Cl..
PR
09/15ARDX NOTICE : ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Los..
PR
09/10INVESTOR ALERT : Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Bee..
BU
09/06KESSLER TOPAZ MELTZER & CHECK, LLP : Reminds Investors of Securities Fraud Class Action Fi..
PR
09/05SHAREHOLDER ALERT : Pomerantz Law Firm Reminds Shareholders with Losses on their Investmen..
PR
09/03ARDELYX : Says Tenapanor Demonstrated Therapeutic Potential in Hyperphosphatemia Study - S..
MT
More news
Analyst Recommendations on ARDELYX, INC.
More recommendations
Financials (USD)
Sales 2021 9,78 M - -
Net income 2021 -138 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,95x
Yield 2021 -
Capitalization 135 M 135 M -
Capi. / Sales 2021 13,8x
Capi. / Sales 2022 8,17x
Nbr of Employees 129
Free-Float 98,4%
Chart ARDELYX, INC.
Duration : Period :
Ardelyx, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARDELYX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 1,31 $
Average target price 4,75 $
Spread / Average Target 263%
EPS Revisions
Managers and Directors
Michael G. Raab President, Chief Executive Officer & Director
Justin A. Renz Chief Financial & Accounting Officer
David M. Mott Chairman
Jeffrey W. Jacobs Chief Scientific Officer
Elizabeth Grammer Secretary, Chief Legal & Administrative Officer
Sector and Competitors
1st jan.Capi. (M$)
ARDELYX, INC.-79.75%135
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634